

Lei Miao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9209106/publications.pdf>

Version: 2024-02-01

41
papers

5,699
citations

126708

33
h-index

288905

40
g-index

41
all docs

41
docs citations

41
times ranked

7209
citing authors

#	ARTICLE	IF	CITATIONS
1	Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. <i>Molecular Therapy</i> , 2019, 27, 710-728.	3.7	685
2	mRNA vaccine for cancer immunotherapy. <i>Molecular Cancer</i> , 2021, 20, 41.	7.9	445
3	Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. <i>Nature Biotechnology</i> , 2019, 37, 1174-1185.	9.4	398
4	Self-Assembled Redox Dual-Responsive Prodrug-Nanosystem Formed by Single Thioether-Bridged Paclitaxel-Fatty Acid Conjugate for Cancer Chemotherapy. <i>Nano Letters</i> , 2016, 16, 5401-5408.	4.5	346
5	Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer. <i>Molecular Therapy</i> , 2018, 26, 45-55.	3.7	240
6	Quercetin Remodels the Tumor Microenvironment To Improve the Permeation, Retention, and Antitumor Effects of Nanoparticles. <i>ACS Nano</i> , 2017, 11, 4916-4925.	7.3	218
7	Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors. <i>Journal of Controlled Release</i> , 2015, 219, 192-204.	4.8	192
8	Esterase-Activated Charge-Reversal Polymer for Fibroblast-Exempt Cancer Gene Therapy. <i>Advanced Materials</i> , 2016, 28, 10613-10622.	11.1	189
9	A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer. <i>JCI Insight</i> , 2018, 3, .	2.3	175
10	Targeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors. <i>Cancer Research</i> , 2017, 77, 719-731.	0.4	169
11	Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver. <i>Nature Communications</i> , 2020, 11, 2424.	5.8	167
12	Co-delivery of Cisplatin and Rapamycin for Enhanced Anticancer Therapy through Synergistic Effects and Microenvironment Modulation. <i>ACS Nano</i> , 2014, 8, 4996-5009.	7.3	163
13	The Binding Site Barrier Elicited by Tumor-Associated Fibroblasts Interferes Disposition of Nanoparticles in Stroma-Vessel Type Tumors. <i>ACS Nano</i> , 2016, 10, 9243-9258.	7.3	161
14	Delivery of oligonucleotides with lipid nanoparticles. <i>Advanced Drug Delivery Reviews</i> , 2015, 87, 68-80.	6.6	158
15	Nanoparticles with Precise Ratiometric Co-Loading and Co-Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer. <i>Advanced Functional Materials</i> , 2014, 24, 6601-6611.	7.8	154
16	Facile Fabrication of Tumor Redox-Sensitive Nanoassemblies of Small-Molecule Oleate Prodrug as Potent Chemotherapeutic Nanomedicine. <i>Small</i> , 2016, 12, 6353-6362.	5.2	147
17	Nanoformulations for combination or cascade anticancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2017, 115, 3-22.	6.6	145
18	PolyMetformin combines carrier and anticancer activities for in vivo siRNA delivery. <i>Nature Communications</i> , 2016, 7, 11822.	5.8	133

#	ARTICLE	IF	CITATIONS
19	mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma. <i>Molecular Therapy</i> , 2018, 26, 420-434.	3.7	132
20	Lipid-Coated Cisplatin Nanoparticles Induce Neighboring Effect and Exhibit Enhanced Anticancer Efficacy. <i>ACS Nano</i> , 2013, 7, 9896-9904.	7.3	125
21	Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	117
22	Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer. <i>ACS Nano</i> , 2017, 11, 8690-8706.	7.3	108
23	Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model. <i>Journal of Controlled Release</i> , 2014, 182, 90-96.	4.8	105
24	Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin. <i>Journal of Controlled Release</i> , 2015, 217, 27-41.	4.8	101
25	Exploring the Tumor Microenvironment with Nanoparticles. <i>Cancer Treatment and Research</i> , 2015, 166, 193-226.	0.2	97
26	Curcumin Micelles Remodel Tumor Microenvironment and Enhance Vaccine Activity in an Advanced Melanoma Model. <i>Molecular Therapy</i> , 2016, 24, 364-374.	3.7	86
27	Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer. <i>Journal of Controlled Release</i> , 2016, 244, 63-73.	4.8	74
28	Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapy. <i>Journal of Controlled Release</i> , 2014, 174, 137-142.	4.8	71
29	A novel cationic lipid with intrinsic antitumor activity to facilitate gene therapy of TRAIL DNA. <i>Biomaterials</i> , 2016, 102, 239-248.	5.7	59
30	Nanoparticle cancer vaccines: Design considerations and recent advances. <i>Asian Journal of Pharmaceutical Sciences</i> , 2020, 15, 576-590.	4.3	58
31	Understanding the synergistic effect of physicochemical properties of nanoparticles and their cellular entry pathways. <i>Communications Biology</i> , 2020, 3, 205.	2.0	57
32	Sigma receptor-mediated targeted delivery of anti-angiogenic multifunctional nanodrugs for combination tumor therapy. <i>Journal of Controlled Release</i> , 2016, 228, 107-119.	4.8	45
33	Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach. <i>Cancer Letters</i> , 2016, 379, 32-38.	3.2	41
34	A Low Protein Binding Cationic Poly(2-oxazoline) as Non-Viral Vector. <i>Macromolecular Bioscience</i> , 2015, 15, 1004-1020.	2.1	37
35	Dual Functional LipoMET Mediates Envelope-type Nanoparticles to Combinational Oncogene Silencing and Tumor Growth Inhibition. <i>Molecular Therapy</i> , 2017, 25, 1567-1579.	3.7	28
36	Using a Physiologically Based Pharmacokinetic Absorption Model to Establish Dissolution Bioequivalence Safe Space for Osetamivir in Adult and Pediatric Populations. <i>AAPS Journal</i> , 2020, 22, 107.	2.2	24

#	ARTICLE	IF	CITATIONS
37	Remodeling the fibrotic tumor microenvironment of desmoplastic melanoma to facilitate vaccine immunotherapy. <i>Nanoscale</i> , 2020, 12, 3400-3410.	2.8	24
38	Turning a water and oil insoluble cisplatin derivative into a nanoparticle formulation for cancer therapy. <i>Biomaterials</i> , 2014, 35, 7647-7653.	5.7	22
39	Cancer Therapy: Esterase-Activated Charge-Reversal Polymer for Fibroblast-Exempt Cancer Gene Therapy (<i>Adv. Mater.</i> 48/2016). <i>Advanced Materials</i> , 2016, 28, 10578-10578.	11.1	2
40	Pieter Cullis: an outstanding lipid biophysicist, drug delivery scientist, educator, and entrepreneur. <i>Journal of Drug Targeting</i> , 2016, 24, 762-764.	2.1	1
41	Abstract 1173: A novel selective Mcl-1 inhibitor exhibits <i>in vitro</i> and <i>in vivo</i> efficacy in melanoma. , 2017, , .		0